Interleukin 6, Recombinant, Human (Interleukin-6, IL6, IL-6, B-cell Stimulatory Factor 2, BSF2, BSF-2, CTL Differentiation Factor, CDF, Hybridoma Growth Factor, HGF, HSF, Interferon beta-2, IFN-beta-2, IFNB2)

Source:\nRecombinant corresponding to 184aa of human Interleukin-6 expressed in E.coli is a single, non-glycosylated polypeptide chain.\n\nMolecular Weight:\n~21kD\n\nBiological Activity:\nThe ED50 as determined by the dose-dependent stimulation of mouse 7TD1 cellsis less then 0.1ng/ml, corresponding to a Specific Activity of 5x107 IU/mg.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.47 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of IL-6 as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8428-32H

Size

20ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. Production of soluble human interleukin-6 in cytoplasm by fed-batch culture of recombinant E. coli. Biotechnol Prog 2005 Mar-Apr;21(2):524-31. 2. Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans. Am J Physiol Endocrinol Metab 2005 Jul;289(1):E2-7. 3. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J Biol Chem 2004 Dec 10;279(50):51793-803. 4. Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur J Immunogenet 2003 Dec;30(6):397-400. 5. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003 Oct 3;278(40):38829-39. 6. Effect of in situ expression of human interleukin-6 on antibody responses against Salmonella typhimurium antigens. FEMS Immunol Med Microbiol 2003 Jul 15;37(2-3):135-45.

Alternative Names

Interleukin 6 (Interferon, beta 2)